SUMMARY
Acute myeloid leukemia is the most common type of leukemia in adult population, accounting for about 34 % of adult leukemias. Its incidence increases with age. The backbone of treatment is still combined systemic chemotherapy. Unfortunately, with the current treatment only one third of patients with this disease survive 5 years. The prognosis in older patients is worse with 5-years overall survival less than 10 %. Numerous genetic abnormalities indicate a high heterogeneity of the disease and a diverse response to treatment. The prognosis has improved in recent years due to new treatment approaches, better knowledge of the biology of the disease, better stratification of risk groups, rational indication of stem cell transplantation and better supportive and intensive therapy. This paper will focus on the management of acute myeloid leukemia in the new era of personalized medicine, summarize the available evidence, and highlight optimal treatment strategies.

Key words: acute myeloid leukemia, target therapy, chemotherapy, personalized medicine, prognosis.
Lek Obz, 2021, 70(10): 364-371

Firas FARKAŠ

Klinika hematológie a transfúziológie, LF UK, SZU a UNB, Bratislava, prednostka prof. MUDr. A. Bátorová, PhD.

Cite:
FARKAŠ F.: Optimization of therapy for acute myeloid leukemia in the era of novel drugs. Lek Obz, 2021, 70(10): 364-371